MENU

Medical Developments International Ltd (ASX:MVP) shares rocket on China expansion plans

One of the best performers on the market on Monday has been the Medical Developments International Ltd (ASX: MVP) share price.

In late morning trade the healthcare company’s shares are up over 14% to $5.60. At one stage its shares were up as much as 19% to $5.84.

Why are Medical Developments International’s shares rocketing higher?

This morning the company announced that it has entered into an exclusive distribution and license agreement with Japan-based Daiichi Sankyo Company for Penthrox in China, Thailand, and Vietnam.

Daiichi Sankyo Company is a global pharmaceutical company and the second largest pharmaceutical company in Japan.

According to the release, the agreement will see Daiichi Sankyo Company pay Medical Developments International up to US$32.5 million (A$45.8 million), including US$15 million upfront (A$21.1 million), and sales-based milestone payments.

In addition to this, the two parties will enter into a master service agreement with Japan’s leading full clinical and regulatory service provider, EPS International, to get Penthrox approved for sale in China.

Medical Developments International will fund the approval process up to US$10 million and will own the intellectual property generated from the program. The company will also be the owner of the “Drug Import License” once Penthrox is approved.

CEO, John Sharman appears to be pleased with the latest expansion of the “green whistle” product. He stated that: “We are delighted to partner with Daiichi Sankyo, one of Japan’s biggest pharmaceutical companies. Daiichi Sankyo shares our vision for the potential of Penthrox in China, Thailand and Vietnam.”

He added that: “Acute pain in trauma and minor surgical procedures is undertreated in the Chinese healthcare system. MVP believes there is an important place for Penthrox in pain management in China. Penthrox, with its fact acting, non-addictive, non-opioid characteristics will be an important tool for pain management in the Chinese, Vietnamese and Thai markets.”

Should you invest?

I can’t say I’m surprised by the share price reaction today. If the company can achieve regulatory approval for the product in China and is able to successfully penetrate the market, it could be a game-changer.

However, I would suggest investors keep their powder dry for now and wait to see if approval is achieved. Especially given the issues the company is having getting Penthrox approved by the U.S. FDA.

In the meantime, I would suggest investors consider industry peers CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX).

Alternatively, this buy rated growth share could be even better. Do you own it?

Top Australian Stock Picker Just Issued Rare “Double Down” Buy Alert

Discover why this legendary Australian stock-picker just issued a “Double Down” buy alert to his exclusive group of insiders… and why he’s convinced this might be the single most attractive entry point for years to come.

Simply click here to get started and access our secure sign-up page.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.